Search

Displaying results 1301 - 1310 of 10000 in total
  1. Drug

    Dyphylline

    go.drugbank.com/drugs/DB00651
    ApprovedWithdrawn

    It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.

    Mixtures: Dy G, Dyphylline GG ES
  2. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.[L43862] … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt

  3. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency.

    Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, Beriplex P/n 500
  4. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.

    Categories: Dopamine D2 Receptor Antagonists
  5. Drug

    Amikacin

    go.drugbank.com/drugs/DB00479
    ApprovedInvestigationalVet approved

    of patients with the disease who do not respond to traditional treatment. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population

    Synonyms: D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-, -D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE
  6. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. … [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single

  7. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. … Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada.

    Products: ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRINGE 20MCG/ML, ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRINGE 10mcg/0.5ml
  8. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. … [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

  9. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].

  10. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.